2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .: Verified by Johnson & Johnson , 2 sept 09 . Fase III Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy ( TRS ) .

04 septiembre 2009

Verified by Johnson & Johnson , 2 sept 09 . Fase III Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy ( TRS ) .

A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS).

...